Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enanta Pharmaceuticals, a developer of small molecule anti-infective drugs, has initiated a Phase Ia study on investigational oral antibiotic EDP-322, a methicillin-resistant Staphylococcus aureus-active Bicyclolide, a novel macrolide-related drug class with a distinct resistance profile.
Subscribe to our email newsletter
The Phase Ia, double-blind, placebo controlled study for EDP-322 announced is a single ascending dose trial in healthy volunteers.
The clinical development program for EDP-322 will include the treatment of hospital- and community-acquired gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA).
Preclinically, EDP-322 has demonstrated strong in vitro activity against hospital-acquired MRSA strains resistant to vancomycin, Zyvox (linezolid), and Cubicin (daptomycin), the company said.
Yat Sun, senior vice president of R&D at Enanta, said: “The potency of EDP-322 against hospital-acquired MRSA, community-acquired MRSA, and other gram-positive pathogens, combined with the convenience of oral administration, has the potential to uniquely position EDP-322 among marketed MRSA drugs in both the hospital and community settings.”